-
公开(公告)号：US09878048B2
公开(公告)日：2018-01-30
申请号：US15232714
申请日：2016-08-09
IPC分类号： C07K16/28 , C07K14/705 , A61K39/008 , A61K47/48 , A61K9/107 , A61K9/51 , A61K39/00 , C07K7/08 , C07K16/18 , C07K14/62 , C07K14/74 , C12N9/82 , C12N9/96 , A61K38/00
CPC分类号： A61K47/6811 , A61K9/1075 , A61K9/513 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/64 , A61K47/6803 , A61K47/6815 , A61K47/6843 , A61K47/6849 , A61K2039/6031 , A61K2039/605 , A61K2039/6056 , C07K7/08 , C07K14/62 , C07K14/70539 , C07K16/18 , C07K16/28 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/30 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , C12N9/82 , C12N9/96 , C12Y305/01001
摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
-
公开(公告)号：US09814780B2
公开(公告)日：2017-11-14
申请号：US15232694
申请日：2016-08-09
IPC分类号： A61K38/00 , A61K47/48 , A61K9/107 , A61K9/51 , A61K39/00 , C07K7/08 , C07K16/18 , C07K14/62 , C07K14/74 , C12N9/82 , C07K16/28 , C12N9/96
CPC分类号： A61K47/6811 , A61K9/1075 , A61K9/513 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/64 , A61K47/6803 , A61K47/6815 , A61K47/6843 , A61K47/6849 , A61K2039/6031 , A61K2039/605 , A61K2039/6056 , C07K7/08 , C07K14/62 , C07K14/70539 , C07K16/18 , C07K16/28 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/30 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , C12N9/82 , C12N9/96 , C12Y305/01001
摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
-
公开(公告)号：US20170066825A1
公开(公告)日：2017-03-09
申请号：US15357999
申请日：2016-11-21
CPC分类号： C07K16/28 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/6849 , A61K2039/505 , A61K2039/6031 , A61K2039/6056 , B82Y5/00 , C07K7/08 , C07K14/4701 , C07K14/77 , C07K16/18 , C07K16/30 , C07K2317/34 , C07K2317/622 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , A61K2039/57 , A61K2039/577
摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
摘要翻译： 描述了特异性结合红细胞的肽。 这些作为肽配体提供，其具有与红细胞特异性结合的序列，或作为提供特异性结合的抗体或其片段。 肽可以制备成具有治疗剂，耐受抗原或靶向肽的分子融合物。 可以通过使用融合物和在需要耐受性的物质上选择抗原来产生免疫耐受性。 与靶向肽的融合将融合物引导到靶，例如肿瘤，其中红细胞结合配体通过向目标募集红细胞而减少或完全消除血液流向肿瘤的血液。
-
公开(公告)号：US20160354484A1
公开(公告)日：2016-12-08
申请号：US15232694
申请日：2016-08-09
CPC分类号： A61K47/6811 , A61K9/1075 , A61K9/513 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/64 , A61K47/6803 , A61K47/6815 , A61K47/6843 , A61K47/6849 , A61K2039/6031 , A61K2039/605 , A61K2039/6056 , C07K7/08 , C07K14/62 , C07K14/70539 , C07K16/18 , C07K16/28 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/30 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , C12N9/82 , C12N9/96 , C12Y305/01001
摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
摘要翻译： 描述了特异性结合红细胞的肽。 这些作为肽配体提供，其具有与红细胞特异性结合的序列，或作为提供特异性结合的抗体或其片段。 肽可以制备成具有治疗剂，耐受抗原或靶向肽的分子融合物。 可以通过使用融合物和在需要耐受性的物质上选择抗原来产生免疫耐受性。
-
公开(公告)号：US10392437B2
公开(公告)日：2019-08-27
申请号：US15357999
申请日：2016-11-21
IPC分类号： B82Y5/00 , C07K7/08 , A61K38/00 , A61K39/00 , A61K47/68 , C07K14/47 , C07K14/77 , C07K16/18 , C07K16/28 , C07K16/30
摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
-
公开(公告)号：US20180303951A1
公开(公告)日：2018-10-25
申请号：US16028209
申请日：2018-07-05
IPC分类号： A61K47/64 , C07K16/28 , A61K38/08 , A61K38/16 , A61K38/17 , A61K38/20 , C07K16/24 , A61K38/28 , A61K39/35 , A61K39/00 , A61K38/38 , A61K38/37 , A61K47/54 , A61K38/00
CPC分类号： A61K47/549 , A61K38/00 , A61K38/08 , A61K38/164 , A61K38/1709 , A61K38/2013 , A61K38/28 , A61K38/37 , A61K38/38 , A61K39/0002 , A61K39/0005 , A61K39/0008 , A61K39/001 , A61K39/35 , A61K47/64 , A61K2039/577 , A61K2039/60 , A61K2039/6087 , C07K16/241 , C07K16/2848 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2319/01
摘要： Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
-
公开(公告)号：US20160354454A1
公开(公告)日：2016-12-08
申请号：US15232724
申请日：2016-08-09
CPC分类号： A61K47/6811 , A61K9/1075 , A61K9/513 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/64 , A61K47/6803 , A61K47/6815 , A61K47/6843 , A61K47/6849 , A61K2039/6031 , A61K2039/605 , A61K2039/6056 , C07K7/08 , C07K14/62 , C07K14/70539 , C07K16/18 , C07K16/28 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/30 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , C12N9/82 , C12N9/96 , C12Y305/01001
摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
摘要翻译： 描述了特异性结合红细胞的肽。 这些作为肽配体提供，其具有与红细胞特异性结合的序列，或作为提供特异性结合的抗体或其片段。 肽可以制备成具有治疗剂，耐受抗原或靶向肽的分子融合物。 可以通过使用融合物和在需要耐受性的物质上选择抗原来产生免疫耐受性。
-
公开(公告)号：US20160354453A1
公开(公告)日：2016-12-08
申请号：US15232714
申请日：2016-08-09
CPC分类号： A61K47/6811 , A61K9/1075 , A61K9/513 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/64 , A61K47/6803 , A61K47/6815 , A61K47/6843 , A61K47/6849 , A61K2039/6031 , A61K2039/605 , A61K2039/6056 , C07K7/08 , C07K14/62 , C07K14/70539 , C07K16/18 , C07K16/28 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/30 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , C12N9/82 , C12N9/96 , C12Y305/01001
摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
摘要翻译： 描述了特异性结合红细胞的肽。 这些作为肽配体提供，其具有与红细胞特异性结合的序列，或作为提供特异性结合的抗体或其片段。 肽可以制备成具有治疗剂，耐受抗原或靶向肽的分子融合物。 可以通过使用融合物和在需要耐受性的物质上选择抗原来产生免疫耐受性。
-
公开(公告)号：US20230119325A1
公开(公告)日：2023-04-20
申请号：US17810573
申请日：2022-07-01
IPC分类号： A61K47/54 , A61K39/35 , A61K38/28 , A61K47/58 , A61K47/60 , A61K39/385 , A61K39/00 , A61K38/38
摘要： Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
-
公开(公告)号：US20230093483A1
公开(公告)日：2023-03-23
申请号：US17810565
申请日：2022-07-01
摘要： Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.037 秒)
